12 citations,
March 2013 in “Cancer Causes & Control” Early balding, especially frontal, increases prostate cancer risk; more research needed.
10 citations,
June 2010 in “Expert Opinion on Drug Metabolism & Toxicology” Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.
1 citations,
May 2013 in “Journal of the Egyptian Women's Dermatologic Society (Print)” PSA could be a marker for hyperandrogenism in women, but more research is needed.
1 citations,
January 2020 in “Egyptian Journal of Dermatology and Venereology” Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
24 citations,
June 2021 in “Journal of the European Academy of Dermatology and Venereology” Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.
6 citations,
July 2016 in “Gynecological Endocrinology” PSA levels are higher in women with PCOS, but FAI is a more accurate marker for diagnosis.
2 citations,
December 2006 in “Lancet Oncology” Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.
1 citations,
December 2017 in “Journal of The European Academy of Dermatology and Venereology” Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.
16 citations,
April 2007 in “Journal of Obstetrics and Gynaecology Research” Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.
11 citations,
April 2013 in “Journal of Agricultural and Food Chemistry” Monascus helps prevent baldness, prostate issues, and may be a natural alternative to medications.
75 citations,
May 1986 in “Clinics in endocrinology and metabolism” Male hormones are important for hair and oil gland development and can cause conditions like excessive hair growth and acne.
60 citations,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
35 citations,
January 2014 in “Postepy Dermatologii I Alergologii” DHT's role in hair loss is important, but measuring its level for diagnosis is questionable.
8 citations,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
September 2019 in “Human Andrology” Higher serum androgens contribute to male pattern baldness.
16 citations,
January 2019 in “Pharmaceutical biology” Lespedeza cuneata extract may help treat enlarged prostate.
1 citations,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
1 citations,
November 2016 in “Journal of the Dermatology Nurses’ Association” Finasteride treats hair loss but may cause side effects like low libido and dizziness.
March 2024 in “Journal of Pharmaceutical and Sciences” Zaleya pentandra extracts, especially acetone, may be useful for new medicines and food industry applications.
98 citations,
August 2004 in “BJU international” Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.
93 citations,
January 1996 in “Clinical Pharmacokinectics” Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
65 citations,
March 1999 in “Urology” Finasteride didn't significantly improve ICPPS symptoms, more research needed.
33 citations,
October 2004 in “Archives of Dermatological Research” Large prostate links to more hair loss, but age of onset doesn't affect it.
31 citations,
October 2020 in “Journal of nanomaterials” Silver nanoparticles made from Grewia optiva leaf extract show strong antibacterial, antioxidant, and hair growth benefits.
21 citations,
November 2014 in “Journal of Endocrinological Investigation” Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.
20 citations,
February 2009 in “Chemistry & Biodiversity” Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.
November 2020 in “Elsevier eBooks” Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
203 citations,
December 2004 in “Journal of The American Academy of Dermatology” Early diagnosis and treatment, using finasteride, minoxidil, or hair transplantation, improves hair loss outcomes.
198 citations,
October 2011 in “Journal der Deutschen Dermatologischen Gesellschaft” Use minoxidil for hair loss; finasteride and dutasteride for men, dutasteride for women.